sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

1 AI Stock I Wouldn't Touch, and 1 I Absolutely Love

View original at nasdaq.com
“In Q4, the company reported a generally accepted accounting principles (GAAP) net loss of $12.1 million.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Apple's stock has a bullish outlook over the next five years

    60% confidence
  • Apple is well-positioned to capture a multiyear wave of high-margin device sales while also tapping new software and services opportunities in an AI era

    60% confidence
  • Apple gives investors a front-row seat to the consumer AI revolution while providing the safety of a highly profitable, cash-generating business

    60% confidence
  • New annual contract value bookings grew by nearly 50% year over year

    60% confidence
  • Apple will likely be a major AI beneficiary without having to invest the same extraordinary sums that software and cloud providers do

    60% confidence
  • Stock Advisor's total average return is 900% compared to 184% for the S&P 500

    60% confidence
  • Apple wasn't one of the 10 best stocks for investors to buy now

    60% confidence
  • Cloudflare's inability to turn a true profit makes its sky-high valuation too risky

    60% confidence

Data points we hold from this source

Apple Podcasts · price to earnings ratio32 ratio
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
1 AI Stock I Wouldn't Touch, and 1 I Absolutely Love — Source | Via News | pt.VIA.NEWS